Genomics company Illumina (NASDAQ: ILMN) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 9.4% year on year to $1.16 billion. The company’s full-year revenue guidance of $4.62 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.31 per share was 6.8% above analysts’ consensus estimates.

Is now the time to buy ILMN? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Illumina’s second quarter results reflected strong execution in its core clinical sequencing business, with management highlighting robust demand from U.S. and international clinical customers as the primary growth driver. CEO Jacob Thaysen pointed to growing adoption of the NovaSeq X platform and expanding instrument placements, noting that “strong instrument placements over the past three quarters are expanding customer capacity and will support consumable growth for many quarters to come.” While research and academic markets showed some improvement, management emphasized that the clinical segment remained the engine of performance.

Looking forward, Illumina’s raised full-year outlook is underpinned by continued momentum in clinical consumables, the expanding installed base of NovaSeq X, and an emerging pipeline of multi-omics and data-centric offerings. Thaysen said, “The momentum we are seeing, especially from our clinical customers, gives us greater confidence as we enter the second half,” and highlighted the company’s expectation that consumables growth will accelerate as recent instrument placements begin to drive higher usage. Management also pointed to early contributions from BioInsight and new product launches as important signposts for sustained growth.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to elevated NovaSeq X demand, expanding clinical applications, and progress in multi-omics workflows, while noting persistent cost pressures and some regional variability.

• NovaSeq X demand remains high: Even three years post-launch, NovaSeq X placements exceeded 95 units in the quarter, with most sales driven by clinical customers expanding capacity for diagnostic and therapeutic applications. This continued strength supports future consumables revenue as new instruments come online.
• Clinical segment drives growth: Approximately 65% of sequencing consumables revenue came from clinical markets, where U.S.-Canada led with over 20% growth. Management noted the “broad-based” nature of clinical demand, with oncology and rare disease testing as key applications, and called out the U.S. as the primary engine.
• Research markets stabilize: The research and academic segment showed quarter-on-quarter improvement, though management remains cautious due to continued funding uncertainties. Early signs of increased activity, especially in the U.S., could support a gradual recovery, but no material near-term rebound is anticipated.
• Multi-omics and spatial biology expansion: The launch of StrataMap Spatial and traction in proteomics through the SomaLogic acquisition extended Illumina’s reach beyond core sequencing. Management highlighted growing customer interest in integrated genomics, proteomics, and spatial solutions, which are expected to add incremental growth in the coming years.
• Operational discipline amid cost headwinds: Despite higher freight and memory costs, margins came in above expectations due to disciplined expense management and operational efficiency. CFO Ankur Dhingra emphasized that supply chain actions and cost sharing with customers are helping to offset inflationary pressures.

Drivers of Future Performance

Illumina’s updated guidance is driven by sustained clinical demand, a growing instrument base, and the scaling of new data and workflow offerings.

• Consumables growth from installed base: Management expects recent NovaSeq X placements to drive higher consumables revenue as clinical customers ramp up usage, particularly in oncology and rare disease applications. The company forecasts mid-teens clinical consumables growth, which should support overall high-single-digit revenue gains next year.
• Multi-omics and BioInsight contributions: New offerings in spatial biology and proteomics, as well as early revenue from the Billion Cell Atlas data program, are expected to add 1–2 percentage points of growth to the topline in 2027. Management sees these areas as key differentiators in supporting pharmaceutical customers and advancing AI-enabled drug discovery.
• Margin improvement and cost management: Illumina anticipates sequential operating margin expansion in the second half of the year, driven by a favorable mix of consumables, ongoing cost actions, and efforts to mitigate input cost inflation. Management acknowledged ongoing risks from memory and freight costs but expressed confidence in operational levers to maintain profit targets.

Catalysts in Upcoming Quarters

In coming quarters, the StockStory team will be watching (1) how quickly consumables revenue accelerates from the expanded NovaSeq X installed base, (2) early adoption and revenue contributions from new multi-omics and spatial biology offerings like StrataMap and SomaScan, and (3) sustained strength in clinical markets, especially in oncology and rare disease applications. Execution on integrating data-driven solutions such as BioInsight and maintaining margin discipline amid cost pressures will also be important to monitor.

Illumina currently trades at $202.95, down from $205.09 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

Stocks That Trumped Tariffs

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.